KR102750931B1 - 리보시클립 정제 - Google Patents

리보시클립 정제 Download PDF

Info

Publication number
KR102750931B1
KR102750931B1 KR1020177029433A KR20177029433A KR102750931B1 KR 102750931 B1 KR102750931 B1 KR 102750931B1 KR 1020177029433 A KR1020177029433 A KR 1020177029433A KR 20177029433 A KR20177029433 A KR 20177029433A KR 102750931 B1 KR102750931 B1 KR 102750931B1
Authority
KR
South Korea
Prior art keywords
tablet
ribociclib
tablets
delete delete
coating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177029433A
Other languages
English (en)
Korean (ko)
Other versions
KR20170137101A (ko
Inventor
빈두마다반 구루라잔
아르노 그랑듀리
루이 코스타
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102750931(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Priority to KR1020257000051A priority Critical patent/KR20250009572A/ko
Publication of KR20170137101A publication Critical patent/KR20170137101A/ko
Application granted granted Critical
Publication of KR102750931B1 publication Critical patent/KR102750931B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020177029433A 2015-04-16 2016-04-14 리보시클립 정제 Active KR102750931B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257000051A KR20250009572A (ko) 2015-04-16 2016-04-14 리보시클립 정제

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562148240P 2015-04-16 2015-04-16
US62/148,240 2015-04-16
PCT/IB2016/052136 WO2016166703A1 (en) 2015-04-16 2016-04-14 Ribociclib tablet

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257000051A Division KR20250009572A (ko) 2015-04-16 2016-04-14 리보시클립 정제

Publications (2)

Publication Number Publication Date
KR20170137101A KR20170137101A (ko) 2017-12-12
KR102750931B1 true KR102750931B1 (ko) 2025-01-09

Family

ID=55806565

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177029433A Active KR102750931B1 (ko) 2015-04-16 2016-04-14 리보시클립 정제
KR1020257000051A Pending KR20250009572A (ko) 2015-04-16 2016-04-14 리보시클립 정제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257000051A Pending KR20250009572A (ko) 2015-04-16 2016-04-14 리보시클립 정제

Country Status (31)

Country Link
US (6) US10799506B2 (https=)
EP (3) EP3283058B1 (https=)
JP (1) JP2018514523A (https=)
KR (2) KR102750931B1 (https=)
CN (2) CN107530292B (https=)
AR (1) AR104257A1 (https=)
AU (5) AU2016248017A1 (https=)
BR (1) BR112017021283A2 (https=)
CA (1) CA2982425C (https=)
CL (1) CL2017002593A1 (https=)
CO (1) CO2017010510A2 (https=)
DK (2) DK3283058T3 (https=)
EA (1) EA201792290A1 (https=)
EC (1) ECSP17075052A (https=)
ES (2) ES2938261T3 (https=)
FI (2) FI3283058T3 (https=)
HR (2) HRP20260123T1 (https=)
HU (1) HUE061213T2 (https=)
IL (1) IL254818A0 (https=)
LT (1) LT4197530T (https=)
MX (1) MX2017013350A (https=)
PE (1) PE20180035A1 (https=)
PH (1) PH12017501820A1 (https=)
PL (2) PL4197530T3 (https=)
PT (2) PT4197530T (https=)
RS (1) RS67697B1 (https=)
SG (1) SG11201708084PA (https=)
SI (2) SI3283058T1 (https=)
TN (1) TN2017000422A1 (https=)
TW (1) TW201642864A (https=)
WO (1) WO2016166703A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102529049B1 (ko) 2013-08-14 2023-05-08 노파르티스 아게 암의 치료를 위한 조합 요법
HUE061213T2 (hu) 2015-04-16 2023-05-28 Novartis Ag Ribociklib tabletta
CA3048036A1 (en) 2018-07-02 2020-01-02 Apotex Inc Crystalline form of ribociclib succinate
IL320609A (en) 2019-08-26 2025-07-01 Arvinas Operations Inc Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
CR20220342A (es) 2019-12-16 2023-01-23 Lunella Biotech Inc Agentes terapéuticos selectivos contra el cáncer inhibidores cdk4/6
MX2022007487A (es) 2019-12-16 2022-08-04 Lunella Biotech Inc Agentes terapeuticos selectivos contra el cancer inhibidores de cdk4/6.
CA3187241A1 (en) * 2020-08-03 2022-02-10 Krishna Murthy Bhavanasi Pharmaceutical compositions comprising ribociclib
WO2022071787A1 (es) * 2020-09-29 2022-04-07 Laboratorios Silanes S.A. De C.V. Combinaciones farmacéuticas de estatinas y fibratos para el tratamiento y prevención de hiperlipidemias y enfermedades cardiovasculares
WO2022162122A1 (en) 2021-01-29 2022-08-04 Biotx.Ai Gmbh Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
CN117396208A (zh) 2021-07-16 2024-01-12 达纳－法伯癌症研究所公司 细胞周期蛋白依赖性激酶4/6(cdk4/6)和ikzf2(helios)的小分子降解剂及其使用方法
TWI908143B (zh) 2022-01-25 2025-12-11 瑞士商諾華公司 瑞博西尼藥物組成物用於治療癌症之用途
WO2024049926A1 (en) 2022-08-31 2024-03-07 Arvinas Operations, Inc. Dosage regimens of estrogen receptor degraders
EP4626890A1 (en) 2022-12-01 2025-10-08 KRKA, d.d., Novo mesto Ribociclib salts and formulations thereof
KR20250163966A (ko) 2023-03-27 2025-11-21 노파르티스 아게 리보시클립과 아로마타제 저해제를 병용하여 초기 유방암을 치료하는 방법
TW202602868A (zh) 2024-04-15 2026-01-16 瑞士商諾華公司 瑞波西利的藥物組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014097125A1 (en) * 2012-12-20 2014-06-26 Novartis Ag Pharmaceutical combination comprising binimetinib

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5428812A (en) * 1977-08-09 1979-03-03 Yoshitomi Pharmaceut Ind Ltd Preparation of coated tablet
HU225964B1 (en) * 1994-07-12 2008-01-28 Berwind Pharma Service Moisture barrier film coating composition, method, and coated form
GB9414045D0 (en) 1994-07-12 1994-08-31 Berwind Pharma Service Moisture barrier film coating composition, method, and coated form
US6448323B1 (en) * 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
US8871263B2 (en) * 2009-09-24 2014-10-28 Mcneil-Ppc, Inc. Manufacture of tablet in a die utilizing radiofrequency energy and meltable binder
AR083797A1 (es) 2010-11-10 2013-03-20 Novartis Ag Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
EA025033B1 (ru) * 2011-02-11 2016-11-30 Уиста Лэборэтэриз Лтд. Диаминиевые соли фенотиазина и их применение
PT2872482T (pt) * 2012-07-13 2020-09-22 Oncternal Therapeutics Inc Método de tratamento de cancro de mama com modulador seletivo do recetor de andrógeno (sarm)
EP2742940B1 (en) * 2012-12-13 2017-07-26 IP Gesellschaft für Management mbH Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily
UA118846C2 (uk) * 2013-03-21 2019-03-25 Новартіс Аг Комбінована терапія
EP2810644A1 (en) * 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
HUE061213T2 (hu) 2015-04-16 2023-05-28 Novartis Ag Ribociklib tabletta
CN109953966A (zh) * 2017-12-26 2019-07-02 天津耀辰实业发展有限公司 一种含有瑞博西尼的药物组合物及其制备方法
JP7347388B2 (ja) 2020-09-25 2023-09-20 信越化学工業株式会社 紫外線硬化型有機変性シリコーン組成物および硬化物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014097125A1 (en) * 2012-12-20 2014-06-26 Novartis Ag Pharmaceutical combination comprising binimetinib

Also Published As

Publication number Publication date
AR104257A1 (es) 2017-07-05
AU2020250190A1 (en) 2020-11-05
ES3062263T3 (en) 2026-04-09
CN115554257A (zh) 2023-01-03
US20250134893A1 (en) 2025-05-01
US20250127785A1 (en) 2025-04-24
KR20170137101A (ko) 2017-12-12
AU2019201929B2 (en) 2020-07-09
EP3283058A1 (en) 2018-02-21
FI4197530T3 (fi) 2026-02-03
EA201792290A1 (ru) 2018-02-28
AU2022215155A1 (en) 2022-09-01
EP4197530B1 (en) 2025-11-12
US12064434B2 (en) 2024-08-20
EP4620458A2 (en) 2025-09-24
IL254818A0 (en) 2017-12-31
CA2982425C (en) 2023-10-31
SI3283058T1 (sl) 2023-03-31
PL3283058T3 (pl) 2023-03-20
TW201642864A (zh) 2016-12-16
MX2017013350A (es) 2018-01-25
PT3283058T (pt) 2023-02-03
HRP20230053T1 (hr) 2023-03-03
SI4197530T1 (sl) 2026-03-31
BR112017021283A2 (pt) 2018-06-26
WO2016166703A1 (en) 2016-10-20
PL4197530T3 (pl) 2026-03-23
CN107530292B (zh) 2022-11-01
EP4197530A1 (en) 2023-06-21
DK4197530T3 (da) 2026-02-09
HUE061213T2 (hu) 2023-05-28
US20230104792A1 (en) 2023-04-06
PH12017501820A1 (en) 2018-04-23
LT4197530T (lt) 2026-02-25
US10799506B2 (en) 2020-10-13
FI3283058T3 (fi) 2023-03-01
RS67697B1 (sr) 2026-02-27
ES2938261T3 (es) 2023-04-05
CN107530292A (zh) 2018-01-02
PE20180035A1 (es) 2018-01-09
SG11201708084PA (en) 2017-10-30
CA2982425A1 (en) 2016-10-20
DK3283058T3 (da) 2023-02-13
US12419894B2 (en) 2025-09-23
US20180071292A1 (en) 2018-03-15
CL2017002593A1 (es) 2018-05-18
EP4620458A3 (en) 2025-10-22
EP3283058B1 (en) 2022-11-16
AU2016248017A1 (en) 2017-10-19
PT4197530T (pt) 2026-02-05
AU2024227794A1 (en) 2024-11-21
AU2022215155B2 (en) 2024-08-01
TN2017000422A1 (en) 2019-01-16
AU2019201929A1 (en) 2019-04-11
HRP20260123T1 (hr) 2026-03-13
KR20250009572A (ko) 2025-01-17
US20200390771A1 (en) 2020-12-17
ECSP17075052A (es) 2018-02-28
JP2018514523A (ja) 2018-06-07
US20250090531A1 (en) 2025-03-20
CO2017010510A2 (es) 2018-03-20

Similar Documents

Publication Publication Date Title
KR102750931B1 (ko) 리보시클립 정제
JP6402191B2 (ja) コリンアルホスセラートを含有するフィルムコーティング錠剤およびその製造方法
WO2013054872A1 (ja) ７－［４－（４－ベンゾ［ｂ］チオフェン－４－イル－ピペラジン－１－イル）ブトキシ］－１Ｈ－キノリン－２－オン又はその塩を含む錠剤
JP2024009815A (ja) アキシチニブを含有する医薬組成物
HK40089304A (en) Ribociclib tablet
TW202408531A (zh) 包含葡萄糖酸內酯之哌柏西利製劑
HK1243319A1 (en) Ribociclib tablet
HK1243319B (en) Ribociclib tablet
JP6824549B2 (ja) 経口固形製剤およびその製造法
EA042324B1 (ru) Таблетка, содержащая рибоциклиб
JP2020090484A (ja) エルロチニブを有効成分とする医薬錠剤
JP6673798B2 (ja) カペシタビンを有効成分とするフィルムコート医薬製剤
KR100591786B1 (ko) 프란루카스트를 함유하는 약학적 조성물 및 이의 제조 방법
JP2020075923A (ja) エルロチニブを有効成分とする医薬錠剤
NZ731696B2 (en) Method for treating cancer

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20171013

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210414

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230830

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240930

PG1601 Publication of registration